denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Description:
Venous thromboembolism (VTE) remains a leading cause of significant morbidity and mortality. Anticoagulants have changed the natural history of untreated VTE in the majority of patients with over 95% success in reducing recurrence. However, there will always remain a small population of patients that either cannot receive anticoagulation, fail appropriate anticoagulation, or require adjunctive therapy to anticoagulation. This educational session will outline the role of non-anticoagulant interventions used in the management of VTE and clinically important outcomes associated with these strategies.
Dr. Bauer will discuss the role of thrombolytic agents in the treatment of acute pulmonary embolism and deep venous thrombosis. While systemic thrombolysis has not been shown to improve overall outcomes in comparison to anticoagulation alone, this is due to difficulties in performing randomized trials in severely affected patients and the occurrence of intra-cranial hemorrhage in a small percentage of patients. To address these issues, algorithms for identifying patients at high-risk for poor outcomes and data on the use of catheter-directed or reduced systemic doses of thrombolytic agents will be presented. The role of multi-disciplinary pulmonary embolism response teams (PERT) in the management of severely affected patients will also be examined.
Dr. Rajasekhar will examine trends in IVC filter utilization over the past two decades. Using a case-based approach she will outline the evidence for (and against) IVC filter use in various common clinical scenarios. Where possible, evidence-based recommendations on appropriate use of these devices will be outlined. In areas where a lack of strong evidence exists, expert opinion will be highlighted. Short-term and long-term complications associated with IVC filters and suggestions for IVC filter retrieval will be discussed. The presentation will conclude with a holistic approach on best practices surrounding IVC filters.
Dr. Breen will discuss the role of venous stenting in patients with acute and chronic presentations of venous thromboembolism. She will present a clinical case and discuss how stenting may be considered as an option in addition to current practices of anticoagulation, thrombolysis or compression hosiery in patients who have post- thrombotic syndrome or who have had lysis for acute deep vein thrombosis. She will discuss the current evidence base for the use of venous stenting and address some of the challenges that may influence patient outcomes
Dr. Bauer will discuss the role of thrombolytic agents in the treatment of acute pulmonary embolism and deep venous thrombosis. While systemic thrombolysis has not been shown to improve overall outcomes in comparison to anticoagulation alone, this is due to difficulties in performing randomized trials in severely affected patients and the occurrence of intra-cranial hemorrhage in a small percentage of patients. To address these issues, algorithms for identifying patients at high-risk for poor outcomes and data on the use of catheter-directed or reduced systemic doses of thrombolytic agents will be presented. The role of multi-disciplinary pulmonary embolism response teams (PERT) in the management of severely affected patients will also be examined.
Dr. Rajasekhar will examine trends in IVC filter utilization over the past two decades. Using a case-based approach she will outline the evidence for (and against) IVC filter use in various common clinical scenarios. Where possible, evidence-based recommendations on appropriate use of these devices will be outlined. In areas where a lack of strong evidence exists, expert opinion will be highlighted. Short-term and long-term complications associated with IVC filters and suggestions for IVC filter retrieval will be discussed. The presentation will conclude with a holistic approach on best practices surrounding IVC filters.
Dr. Breen will discuss the role of venous stenting in patients with acute and chronic presentations of venous thromboembolism. She will present a clinical case and discuss how stenting may be considered as an option in addition to current practices of anticoagulation, thrombolysis or compression hosiery in patients who have post- thrombotic syndrome or who have had lysis for acute deep vein thrombosis. She will discuss the current evidence base for the use of venous stenting and address some of the challenges that may influence patient outcomes